INNMFAmplia Therapeutics Ltd.

About Amplia Therapeutics Ltd. (INNMF)

Amplia Therapeutics Ltd. (INNMF) is a Biotechnology company headquartered in Melbourne, VA, Australia whose shares trade over-the-counter on the Pink tier.

Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney.

INNMF key facts

Ticker symbol

INNMF

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

Melbourne, VA, Australia

Country of incorporation

AU

Estimated market cap

$4.18M (as of May 8, 2025)

Shares outstanding

145,548,817

Reporting standard

International Reporting: ASX - Australian Securities Exchange

Audit status

Audited

Fiscal year end

3/31

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with I